Short Selling: Pilbara Minerals and Syrah Resources remain the most shorted stocks on the ASX
Shorters continue to pile into household battery metal names like Pilbara Minerals and Syrah.
Source: iStock
Mentioned
KEY POINTS
- There were no major changes in the most shorted stocks on the ASX over the past week
- Janus Henderson is delisting from the ASX. The company said that the benefits of maintaining the ASX listing no longer outweigh the costs
- Shorts are rising in Imugene after its shares rallied as much as 250% between 1-10 November
Welcome back to the Short Seller Series, where we delve into the most heavily shorted stocks on the ASX and highlight those with significant changes over the past week.
Short selling data is four days behind today's date because reporting is not mandatory until three business days after the trade. The tables below compares short interest changes between 9 November and 15 November.
Most shorted stocks
Ticker | Company | Short % | Prev | % Chg |
|---|---|---|---|---|
Pilbara Minerals | 18.37% | 17.70% | 0.67% | |
Syrah Resources | 17.28% | 15.95% | 1.33% | |
Genesis Minerals | 10.59% | 10.66% | -0.07% | |
Core Lithium | 10.04% | 10.34% | -0.30% | |
Appen | 9.86% | 10.13% | -0.27% | |
Idp Education | 9.69% | 9.96% | -0.27% | |
Sayona Mining | 9.38% | 9.38% | 0.00% | |
Flight Centre | 9.37% | 9.34% | 0.03% | |
Bank of Queensland | 8.50% | 9.07% | -0.57% |
Different week, same shorts: Another incremental week for the most shorted stocks. Shorters continue to pile into household battery metal names like Pilbara Minerals and Syrah Resources. Short interest in PLS has been relentless, up almost threefold since July.
Pilbara Minerals 12-month short interest chart (Source: Shortman)
Most Short Covered Stocks
Ticker | Company | Short % | Prev | % Chg |
|---|---|---|---|---|
Janus Henderson | 1.29% | 4.73% | -3.44% | |
Domino's Pizza | 4.67% | 6.18% | -1.51% | |
Paradigm Biopharmaceuticals | 1.16% | 2.60% | -1.44% | |
Elders | 5.95% | 7.27% | -1.32% | |
United Malt | 0.31% | 1.40% | -1.09% | |
Treasury Wine Estates | 1.53% | 2.39% | -0.86% | |
Solvar | 1.71% | 2.46% | -0.75% | |
The a2 Milk Company | 4.41% | 5.06% | -0.65% | |
Credit Corp Group | 2.17% | 2.76% | -0.59% | |
Sims | 3.50% | 4.08% | -0.58% | |
Bank of Queensland | 8.50% | 9.07% | -0.57% | |
Insignia Financial | 7.09% | 7.65% | -0.56% | |
Green Technology Metals | 0.37% | 0.88% | -0.51% |
Janus Henderson (ASX: JHG) plans to de-list from the ASX on December 6. The company said that "the benefits to the company’s shareholders of maintaining the ASX listing no longer outweigh the financial, administrative and compliance obligations and cost." Earlier this month, the US$4bn fund manager posted better-than-expected third quarter results, with revenue up 1.6% year-on-year to $521.0 million, ahead of analyst expectations of $510.1 million. The company's shares will continue to trade on the NYSE under the same ticker.
Domino's (ASX: DMP) was upgraded to Outperform from Neutral at Macquarie on 20 November. The target price was increased to $58.0 from $54.0. Macquarie raised its FY25-26 EPS forecasts by 2.1% and 4.6% respectively to reflect improved store profitability following the launch of higher margin products.
Stocks with Rising Short Interest
Ticker | Company | Short % | Prev | % Chg |
|---|---|---|---|---|
Imugene | 7.48% | 5.48% | 2.00% | |
Syrah Resources | 17.28% | 15.95% | 1.33% | |
Champion Iron | 2.68% | 1.73% | 0.95% | |
Reliance Worldwide | 1.80% | 0.91% | 0.89% | |
Zip | 4.85% | 4.12% | 0.73% | |
Pilbara Minerals | 18.37% | 17.70% | 0.67% | |
Nine Entertainment | 5.49% | 4.86% | 0.63% | |
Lovisa | 2.64% | 2.02% | 0.62% | |
Healius | 1.94% | 1.34% | 0.60% | |
GPT Group | 1.76% | 1.19% | 0.57% |
Imugene (ASX: IMU) shares rallied as much as 250% between 1-10 November. The key catalysts include:
November 2: Phase 1 MAST (metastatic advanced solid tumours) trial evaluating the safety of novel cancer-killing virus reached a significant milestone.
November 6: Positive early signs from a potential cancer-killing virus VAXINIA.
November 10: Azer-cel, a type of cell therapy, hit a major milestone with first patient dosed with Phase 1B Allogeneic Car T
The stock has almost halved from its brief high of 15 cents on Friday, 10 November. Its currently down 11% to 84 cents in afternoon trade.
